The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

The symptoms of drug-induced skin reactions can range from ... can appear as discoloration, bumps, blisters, urticaria (hives), itching, or peeling of the skin. The symptoms can occur within ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria ... than a decade. The drug is now approved ...

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing to sell the asset while liquidating the business. The writing was on the ...

The patient reported no known drug allergies, unusual exposures, history of hypersensitivity, dermatologic reactions (i.e., atopy, angioedema, or urticaria), or history of seizures. On day 4 of ...